-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back at November 2021, companies in the pharmaceutical industry took frequent actions
.
For example, a number of pharmaceutical companies' science and technology innovation board IPOs have been suspended for consideration, CStone Pharmaceuticals and Hengrui Pharmaceuticals "marriage", Kailaiying signed overseas orders.
.
.
I have briefly sorted out this, let's take a look
.
"Marriage" continues On November 22, Connoa announced that it has exclusively authorized the development and development of an anti-TSLP recombinant humanized monoclonal antibody CM326 for respiratory diseases such as moderate to severe asthma and chronic obstructive pulmonary disease (COPD) with CSPC.
Commercialization officially signed an agreement
.
Conoya will receive a RMB 100 million down payment from CSPC, a development milestone payment of up to RMB 100 million, a sales milestone payment and a sales commission
.
On November 21, CStone Pharmaceuticals and Hengrui Pharmaceuticals jointly announced that the two parties have reached a strategic cooperation and exclusive license agreement for the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region
.
According to the agreement, Hengrui Pharmaceuticals will pay CStone Pharmaceuticals up to approximately US$200 million (approximately 1.
3 billion yuan) in down payment and milestone payments.
CStone Pharmaceuticals will grant Hengrui Pharmaceuticals to the anti-CTLA-4 monoclonal antibody CS1002 in Greater China.
The exclusive right of regional research and development, registration, production and commercialization, and the permitted use is for all human and animal diseases
.
On November 11, Jichuan Pharmaceutical issued an announcement stating that the company reached an agreement with Tianjing Bio to obtain the development, production and commercialization of Tianjing Bio’s long-acting recombinant human growth hormone Itan growth hormone (TJ101) in mainland China Exclusive license, the total transaction amount does not exceed RMB 2.
016 billion
.
From the perspective of the industry, in the past, multinational pharmaceutical companies often talked about cooperation with local pharmaceutical companies.
However, with the development of China's innovative drug industry and the increase in research and development of local companies, more and more local drugs will appear.
In the case of enterprise alliances, enterprises can better promote research and development, accelerate the commercialization process, and better benefit more patients through complementary advantages
.
"Signing a large order" Kalyin issued an announcement on the evening of November 16 that the company signed a new batch of "supply contracts" for related products with a large pharmaceutical company in the United States.
The order is a CDMO order for a small molecule innovative drug related to a customer , The total order size is about 217 million U.
S.
dollars, more than 50% of the company’s operating income last year
.
The company stated that it is inconvenient to disclose customer and product-related information according to the relevant agreements signed between the company and the customer due to the involvement of customer trade secrets.
At the same time, the company also revealed that the counterparty is a large US pharmaceutical company with good credit and good performance capabilities
.
According to the announcement of the Shanghai Stock Exchange on the evening of November 11, the IPO of a number of pharmaceutical companies has been suspended for consideration
.
In the issuance review meeting, the issuance review committee mainly raised more questions about the company's problems in the sale of posaconazole through the overseas distributor LANNETT
.
In addition, on the evening of November 26, Suoyuan Bio also announced the termination of the IPO.
The company responded to relevant media and stated that the company has made a series of progress in the development and operation of multiple pipelines recently, and capital operation and business development also need to be adjusted in time.
Therefore, the application for listing on the Science and Technology Innovation Board was withdrawn voluntarily
.
According to incomplete statistics, at least 16 biomedical companies have terminated their IPOs in the first 11 months of this year, which is higher than the sum of the previous two years
.
Judging from the notices of termination of IPO review of most companies on the STAR Market, independent research and development capabilities and core technologies have received high attention.
It can be seen that the IPO of pharmaceutical companies on the STAR Market needs to focus on these issues
.
.
For example, a number of pharmaceutical companies' science and technology innovation board IPOs have been suspended for consideration, CStone Pharmaceuticals and Hengrui Pharmaceuticals "marriage", Kailaiying signed overseas orders.
.
.
I have briefly sorted out this, let's take a look
.
"Marriage" continues On November 22, Connoa announced that it has exclusively authorized the development and development of an anti-TSLP recombinant humanized monoclonal antibody CM326 for respiratory diseases such as moderate to severe asthma and chronic obstructive pulmonary disease (COPD) with CSPC.
Commercialization officially signed an agreement
.
Conoya will receive a RMB 100 million down payment from CSPC, a development milestone payment of up to RMB 100 million, a sales milestone payment and a sales commission
.
On November 21, CStone Pharmaceuticals and Hengrui Pharmaceuticals jointly announced that the two parties have reached a strategic cooperation and exclusive license agreement for the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region
.
According to the agreement, Hengrui Pharmaceuticals will pay CStone Pharmaceuticals up to approximately US$200 million (approximately 1.
3 billion yuan) in down payment and milestone payments.
CStone Pharmaceuticals will grant Hengrui Pharmaceuticals to the anti-CTLA-4 monoclonal antibody CS1002 in Greater China.
The exclusive right of regional research and development, registration, production and commercialization, and the permitted use is for all human and animal diseases
.
On November 11, Jichuan Pharmaceutical issued an announcement stating that the company reached an agreement with Tianjing Bio to obtain the development, production and commercialization of Tianjing Bio’s long-acting recombinant human growth hormone Itan growth hormone (TJ101) in mainland China Exclusive license, the total transaction amount does not exceed RMB 2.
016 billion
.
From the perspective of the industry, in the past, multinational pharmaceutical companies often talked about cooperation with local pharmaceutical companies.
However, with the development of China's innovative drug industry and the increase in research and development of local companies, more and more local drugs will appear.
In the case of enterprise alliances, enterprises can better promote research and development, accelerate the commercialization process, and better benefit more patients through complementary advantages
.
"Signing a large order" Kalyin issued an announcement on the evening of November 16 that the company signed a new batch of "supply contracts" for related products with a large pharmaceutical company in the United States.
The order is a CDMO order for a small molecule innovative drug related to a customer , The total order size is about 217 million U.
S.
dollars, more than 50% of the company’s operating income last year
.
The company stated that it is inconvenient to disclose customer and product-related information according to the relevant agreements signed between the company and the customer due to the involvement of customer trade secrets.
At the same time, the company also revealed that the counterparty is a large US pharmaceutical company with good credit and good performance capabilities
.
According to the announcement of the Shanghai Stock Exchange on the evening of November 11, the IPO of a number of pharmaceutical companies has been suspended for consideration
.
In the issuance review meeting, the issuance review committee mainly raised more questions about the company's problems in the sale of posaconazole through the overseas distributor LANNETT
.
In addition, on the evening of November 26, Suoyuan Bio also announced the termination of the IPO.
The company responded to relevant media and stated that the company has made a series of progress in the development and operation of multiple pipelines recently, and capital operation and business development also need to be adjusted in time.
Therefore, the application for listing on the Science and Technology Innovation Board was withdrawn voluntarily
.
According to incomplete statistics, at least 16 biomedical companies have terminated their IPOs in the first 11 months of this year, which is higher than the sum of the previous two years
.
Judging from the notices of termination of IPO review of most companies on the STAR Market, independent research and development capabilities and core technologies have received high attention.
It can be seen that the IPO of pharmaceutical companies on the STAR Market needs to focus on these issues
.
